H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $10 from $12 and keeps a Buy rating on the shares post the Q2 report. The firm expects another clinical update on BDTX-1535 in Q4.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond Therapeutics Reports Strong Financial Turnaround
- Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)
- Black Diamond Therapeutics sees cash runway into 4Q27
- Black Diamond, Nike, Apple, Block, IonQ: Trending by Analysts
- Optimistic Buy Rating for Black Diamond Therapeutics: Promising BDTX-1535 Drug and Strong Financial Position